• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

byMichael PratteandTeddy Guo
December 23, 2020
in Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In two phase 1 studies, allogenic anti-CD19 CAR T cell (UCART19) treatment showed a manageable safety profile with relapsed or refractory B-cell acute lymphoblastic leukemia.

2. Allogenic anti-CD19 T cells demonstrated antileukemic activity in both children and adults.

Evidence Rating Level: 2 (Good)

Study Rundown: Although autologous anti-CD19 chimeric antigen receptor (CAR) T cells have demonstrated efficacy in relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL), they are challenging and costly to produce. While, allogenic versions of CAR-T-cell products exist, they are currently hindered by potential safety concerns. UCART19 is an allogenic CAR-T-cell product that has shown efficacy and safety in a small sample of two children and one adult with relapsed B-ALL. Based on these results, two open-labelled, phase 1 studies were launched for patients with relapsed or refractory B-ALL: the PALL trial for children, and the CALM trial for adults. This report is a combination of both trials, which are ongoing at the time of publication. Overall, the most common adverse events reported were cytokine release syndrome (91% of patients), infections (62%) and neurotoxicity (38%). Several grade 3 or higher events occurred, including cytopenia (75% at day 28 post-treatment) and cytokine release syndrome (14%). The overall response rate was 67% for the pooled cohort and 71% were negative for minimal residual disease. An important consideration in this trial when considering pooled results is that lymphodepletion regimens varied between participants, although separate analyses were done for each group.

Click to read the study in The Lancet

Relevant Reading: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.

In-Depth [randomized controlled trial]: These two open-label, non-randomized, ongoing phase 1 trials took place in seven centers across France, the United Kingdom and the USA. A total of 21 patients with relapsed or refractory CD19-positive B-ALL received treatment with UCART19, with 7 children (aged 6 mo-18 years) in the PALL trial and 14 adults (aged 16-70 years) in the CALM trial. The primary endpoint of both trials was adverse events, and secondary endpoints included objective response rate, progress-free survival and overall survival. Patients’ previous treatments were recorded; a median of four (IQR 3-5) was recorded before receiving the trial treatment. The dose of UCART19 received varied according to the patients’ clinical parameters. Overall, the most common adverse events reported were cytokine release syndrome (n=19, 91% of patients), infections (n=13, 62%) and neurotoxicity (n=8, 38%). Grade 3 or greater events included cytokine release syndrome (n=3), infections (n=8), prolonged cytopenia (n=6,) and tumor lysis syndrome (n=2). Two deaths in the CALM trial were associated with dose-limiting UCART19 toxicity. UCART19 showed rapid expansion in-vivo which peaked around 14 days and declined by day 28. An overall response rate of 67% (95% confidence interval [CI] 45-83, n=14) was seen for the pooled cohort with 71% (95% CI 45-88%) being negative for minimal residual disease. Progression-free survival at 6 months was 27% (95% CI 10-47%) and 6-month overall survival was 55% (95% CI 32-74%).

RELATED REPORTS

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

22q11.22 status is a predictor of the degree of negative outcomes of IKZF1 alteration in pediatric B-cell acute lymphoblastic leukemia

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute lymphoblastic leukemiaacute lymphoblastic leukemia (ALL)ALLB-ALLB-cell acute lymphoblastic leukemiaCAR T cellsUCART19
Previous Post

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

Next Post

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

RelatedReports

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia
StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

April 8, 2022
Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors
Endocrinology

22q11.22 status is a predictor of the degree of negative outcomes of IKZF1 alteration in pediatric B-cell acute lymphoblastic leukemia

August 26, 2021
Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors
Chronic Disease

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

August 17, 2021
#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes
StudyGraphics

#VisualAbstract Phase I: Adding carfilzomib to HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia showed favourable safety and efficacy outcomes

February 19, 2021
Next Post
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

MMF and rituximab combination effective in nephrotic syndrome

Special Report: Vaccines in Development Part 4: Johnson & Johnson vaccine as another frontrunner

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Similar perinatal outcomes observed amongst conception via natural and assisted reproductive means
  • Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus
  • Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options